APOGEE BIOTECHNOLOGY CORP.
Apogee is dedicated to developing its sphingosine kinase inhibitor program for the treatment of solid tumors and a variety of chronic inflammatory diseases as well as in indications of damaging acute inflammation. Their product pipeline includes small molecule inhibitors of sphingosine kinase. Sphingosine kinase generates sphingosine-1-phosphate which drives many cancer types and inflammatory diseases and disorders. Their main disease focus is using their technologies to treat solid tumor cancers that have been validated in preclinical animal tumor models including renal cell carcinoma, breast, brain, pancreatic, myeloma and colon cancers.
APOGEE BIOTECHNOLOGY CORP.
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2001-01-01
Address:
Hummelstown, Pennsylvania, United States
Country:
United States
Website Url:
http://www.apogee-biotech.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Euro U.S. Server Location
Similar Organizations
DNAmicroarray
DNAmicroarray is a California corporation with a global presence focused on the development
Neumedicines
Neumedicines is a biotechnology company that focuses on the development of protein therapeutics.
Recensa Therapeutics
Recensa Therapeutics, Inc. has a new approach to treating psoriasis: targeting oxidative stress.
Current Employees Featured
Official Site Inspections
http://www.apogee-biotech.com
- Host name: 144.208.77.246
- IP address: 144.208.77.246
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Apogee Biotechnology Corp."
Apogee Biotechnology Corporation
Apogee Biotechnology Corporation was founded in 2001 by Charles D. Smith, Ph.D. and is based at the Hershey Center for Applied Research in Hershey, Pennsylvania. Apogee is developing …See details»
Apogee Therapeutics | Best-in-Class Therapies for …
Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways. pipeline; People; investors; careers; Pipeline. Reshaping the standard of care for inflammatory and …See details»
Apogee Therapeutics | Best-in-Class Therapies for Immunological …
Apogee Therapeutics, Inc. is a biotechnology company advancing novel, best-in-class therapies to address patients' needs. ... Mr. McKenna raised more than a $1 billion in private and public …See details»
Apogee Therapeutics - Crunchbase Company Profile
Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders. Search Crunchbase. Start Free …See details»
Release Details - Apogee Therapeutics, Inc.
Aug 7, 2023 “The initiation of this Phase 1 study of APG777 represents an important advancement for Apogee, now a clinical-stage organization, and for our discovery research …See details»
Apogee Therapeutics Launches with $169 Million to …
Dec 7, 2022 Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory ...See details»
Immune drug developer Apogee emerges as first spinout of …
Dec 7, 2022 The new biotech launches with $169 million in venture funding and plans to advance its first drug into clinical testing next year. ... Apogee’s public launch follows the …See details»
Paragon spinout Apogee makes debut with $169M
Dec 7, 2022 Paragon Therapeutics has launched its first spinout, dubbed Apogee Therapeutics. The California company already touts a sizable $169 million to advance at least four of Paragon’s preclinical ...See details»
Apogee Therapeutics Launches with $169 Million to Develop …
Dec 7, 2022 Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological …See details»
Apogee Therapeutics Announces Agenda for Virtual R&D Day
2 days ago SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company …See details»
Apogee Therapeutics | Meet The People that Power Progress
The Apogee team is comprised of experienced leaders, drug developers, physicians, and operators. pipeline; People; investors; careers; People. The people that power progress. Our …See details»
Apogee Biotechnology Corporation
The manuscript “Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy” has been published. Int J Mol Sci. 2023 Nov 29;24(23):16901. …See details»
Apogee Therapeutics Announces First Participants Dosed in
Aug 19, 2024 Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced …See details»
Apogee Highlights Corporate Progress and Reports Second
Aug 28, 2023 Apogee expects initial safety and PK data from the Phase 1 trial in mid-2024, a potentially key de-risking event given APG777 is targeting a validated mechanism and has the …See details»
Apogee Therapeutics Highlights Progress and Best-in-Class …
4 hours ago Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), …See details»
Apogee Therapeutics | Best-in-Class Therapies for Immunological …
Michael Henderson, M.D., joined Apogee in September 2022 and serves as Chief Executive Officer and Board member. He is a proven biotechnology industry leader with expertise in …See details»
Apogee Therapeutics Highlights Pipeline Progress and Reports …
May 13, 2024 The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering …See details»
Technology – Apogee Biotechnology Corporation
Apogee Biotechnology Corporation novel sphingosine kinase inhibitors: (Lead compound, ABC294640) are the only “drug-like” SK inhibitors reported to date; do not inhibit a broad …See details»
Apogee data hint at potential for long-lasting eczema drug
Mar 5, 2024 Dive Insight: The study results represent the first human data from Apogee, which last year became one of the rare preclinical biopharmaceutical companies to succeed in a …See details»